Zacks Investment Research on MSN
ResMed (RMD) earnings expected to grow: What to know ahead of next week's release
The market expects ResMed (RMD) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
ResMed CEO Mick Farrell has become the first leader from the home care sector to chair the board of directors at AdvaMed, the trade association representing major medtech companies.
ResMed's (NYSE:RMD) stock up by 3.2% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be ...
Canaday was named chief of staff for the executive team at Resmed in January 2022. Later that year, she moved into the ...
RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could ...
ResMed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Sma ...
ResMed (NYSE:RMD) supports global respiratory care as s&p 500 chart discussions frame large healthcare organizations.
Zacks Investment Research on MSN
Why ResMed (RMD) is a top growth stock for the long term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
As it continues to take advantage of the gaping hole left in the CPAP machine market by competitor Philips’ ongoing respiratory recall troubles, ResMed is still fine-tuning its long-term growth ...
ResMed (RMD) shares recently moved after an earnings report that showed a beat on EPS estimates while revenue matched expectations. Management described fiscal 2026 as off to a strong start. See our ...
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, ...
ResMed (NYSE: RMD), a medical equipment company, has seen an 18% fall in a month, underperforming the broader S&P500 index, up 1%. The recent fall can be attributed to its downbeat Q4 fiscal 2023 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results